Artificial intelligence (AI) software developer Optellum said that its software’s lung cancer prediction technology is eligible for reimbursement nationwide under the U.S. Centers for Medicare and Medicaid Services (CMS) new technology ambulatory payment classification (APC).
Effective July 1, hospitals using Optellum's lung cancer prediction score for quantitative CT tissue characterization -- performed separately from a CT scan -- will be eligible for Medicare reimbursement at a national payment rate of $600-$700 under temporary CPT code 0721T, according to the company.
The lung cancer prediction score is available on Optellum's Virtual Nodule Clinic software, which received U.S. Food and Drug Administration (FDA) 510(k) clearance in 2021.
